ascopubs.org

Randomized Trial of Fixed-Dose Capecitabine Compared With Standard-Dose Capecitabine in Metastatic Breast Cancer: X-7/7 Trial

Efbemalenograstim Alfa, a Long-Acting Granulocyte Colony-Stimulating Factor Fusion Protein Without PEGylation, Versus Pegfilgrastim for Management of Chemotherapy-Induced Neutropenia in Patients With ...
Cure Today

Metronomic Capecitabine and an AI Improve Survival in HR+/HER2– Metastatic Breast Cancer

Metronomic capecitabine plus AI significantly improved PFS and OS in HR-positive, HER2-negative metastatic breast cancer compared to AI alone. The MECCA trial enrolled 263 patients, with balanced ...
ascopubs.org

Real-world effectiveness and safety of adjuvant capecitabine in triple-negative breast cancer (TNBC) patients with residual disease following neoadjuvant chemotherapy.

Three-monthly gonadotropin-releasing hormone agonist for ovarian function suppression in premenopausal breast cancer: A systematic review and meta-analysis. This is an ASCO Meeting Abstract from the ...
Cure Today

What Patients With Cancer Should Know About DPD Deficiency Prior to Chemo

Dr. Gabriel A. Brooks discusses what DPD deficiency is and why it is important for patients with cancer receiving 5-FU or Xeloda to be aware of it. The Food and Drug Administration (FDA) has updated ...
Medscape

FDA Updates Risks in Capecitabine, Fluorouracil Labels

The FDA has updated the product labeling of capecitabine (Xeloda, Genentech) and fluorouracil to reflect the risks of acute toxicity and potentially fatal adverse reactions in patients with ...